Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups

Abstract Background Medulloblastoma (MB) is a heterogeneous disease, displaying distinct genetic profiles with specific molecular subgroups. This study aimed to validate MB subgrouping using surrogate immunohistochemistry and associate subgroups, histopathological types, available clinicopathological parameters overall survival (OS) progression-free (PFS) of patients. included 40 MBs; immunohistochemical staining, β-catenin GRB2-Associated Binding Protein 1 (GAB1) antibodies, was used classify cases into wingless signaling activated (WNT), sonic hedgehog (SHH), non-WNT/SHH Nuclear morphometric analysis (for assessment degree anaplasia) Kaplan-Meier curves were done. Results classified WNT (10%), SHH (30%), (60%) Histopathological types differed significantly according tumor location ( p < 0.001), anaplasia = 0.014), subgroups risk stratification 0.008). Molecular in age distribution 0.031), variants 0.001). OS 77.5% 50% after 2 years, while PFS 65% 27.5% respectively. associated 0.001 0.012 0.005), Conclusions classification based on together indicators, mainly types; accurately stratifies patients predicts their survival.